Anika Therapeutics (ANIK) Tops Q3 EPS by 22c

Anika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.04, $0.22 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $27.8 million versus the consensus estimate of $27.8 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Celcuity (CELC) Reiterates at Market Outperform by Citizens Ahead of Upcoming Launch
• Active options: TSLA NVDA SPCX MU AAPL AMD INTC AMZN AVGO